Comparison Efficiency of Oral Etoricoxib Versus Intravenous Fentanyl on Post Operative Pain in Curettage Under TIVA

Sponsor
Rajavithi Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03697733
Collaborator
(none)
60
1
2
5
12.1

Study Details

Study Description

Brief Summary

Comparison of the efficiency of oral Etoricoxib versus intravenous Fentanyl on post operative Pain in curettage under TIVA: A randomized controlled trial

Condition or Disease Intervention/Treatment Phase
  • Procedure: fractional curettage
N/A

Detailed Description

Fractional Curettage is the most widely used for diagnostic and treatment abnormal uterine bleeding. The patient categorize post-operative pain as mild to moderate. Therefore, the effective analgesic added on intraoperative and post-operative is the most important factor in patient's satisfaction, patient well co-operation, shortness time of operation, decrease unpleasant symptoms and rapid recovery. However, there are many anesthetic technique that can be used to relive pain in the operation such as local anesthesia, total intravenous anesthesia, regional anesthesia or oral analgesic drugs.

Intravenous Fentanyl is an short acting opioid. It has a fast onset of action within 2 minutes and short duration of action 30-60 minutes. Respiratory depression, hypotension and bradycardia are adverse effects that might delayed discharge especially in one day surgery e.g. fractional curettage. Etoricoxib is an oral COX-2 specific inhibitor which can be used to relieve the pain. The onset of analgesia can be occurred within 24 minutes which peak plasma level within 60 minutes. There are many empirical evidences to support the results of post-operative pain after used oral Etoricoxib or intravenous Fentanyl. However, there are less evidences to support efficiency of oral Etoricoxib versus intravenous Fentanyl on post-operative Pain in fractional curettage under TIVA

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficiency of Oral Etoricoxib Versus Intravenous Fentanyl On Post Operative Pain In Curettage Under TIVA : A Randomized Controlled Trial
Actual Study Start Date :
Nov 1, 2018
Actual Primary Completion Date :
Apr 1, 2019
Actual Study Completion Date :
Apr 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Oral Etoricoxib group

Subjects will receive oral Etoricoxib120 mg 30 minutes before fractional curettage then added intravenous Propofol 2 mg/kg when start the procedure

Procedure: fractional curettage
Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure

Placebo Comparator: Intravenous Fentanyl group

Subjects will receive oral placebo [folic acid] 1 tab 30 minutes before the procedure then added intravenous Propofol 2 mg/kg and Intravenous Fentanyl 1 microgram/kg when start the procedure

Procedure: fractional curettage
Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure

Outcome Measures

Primary Outcome Measures

  1. post operative pain [at 60 minute after operation]

    Compare efficacy of oral Etoricoxib and intravenous Fentanyl for post fractional curettage pain by using a visual analog pain scale [Score 0-10]

  2. post operative pain [at 30 minute after operation]

    Compare efficacy of oral Etoricoxib and intravenous Fentanyl for post fractional curettage pain by using a visual analog pain scale [Score 0-10]

  3. post operative pain [at 15 minute after operation]

    Compare efficacy of oral Etoricoxib and intravenous Fentanyl for post fractional curettage pain by using a visual analog pain scale [Score 0-10]

Secondary Outcome Measures

  1. Adverse effect from the drugs during and post operation [since subject receive drugs until 60 minutes after procedure]

    Record subject experience of the following symptoms : nausea and vomiting ,dizziness, drowsiness ,allergic reaction ,chest pain ,and gastrointestinal bleeding or gastrointestinal discomfort

  2. Amount of intravenous Propofol used in the procedure [only intraoperative time]

    Record dose of intravenous Propofol that used in TIVA

  3. The first time pain reliever was used in post operation [within 60 minutes after the procedure]

    Record the first time patient asked for post operative pain reliver or visual analog pain score > 5

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Women who having abnormal uterine bleeding undergoing fractional curettage under TIVA
Exclusion Criteria:
  • Women who have opioid or NSAIDs allergy

  • Women who disagree to participate in this study

  • Women who have history of gastrointestinal bleeding or ulcer

  • Women who have abnormal kidney function

  • Women who can't understand Thai language

  • Women who have American Society of Anesthesiologists [ASA] above 2

  • Women who have been used NSAIDs in 48 hours or often used NSAIDs

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rajavithi Hospital Bangkok Thailand 10400

Sponsors and Collaborators

  • Rajavithi Hospital

Investigators

  • Principal Investigator: apichaya buraputthananon, Rajavithi Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rajavithi Hospital
ClinicalTrials.gov Identifier:
NCT03697733
Other Study ID Numbers:
  • Etovsfen
First Posted:
Oct 5, 2018
Last Update Posted:
Sep 10, 2019
Last Verified:
Oct 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 10, 2019